PL3316867T3 - Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek - Google Patents

Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Info

Publication number
PL3316867T3
PL3316867T3 PL16736730T PL16736730T PL3316867T3 PL 3316867 T3 PL3316867 T3 PL 3316867T3 PL 16736730 T PL16736730 T PL 16736730T PL 16736730 T PL16736730 T PL 16736730T PL 3316867 T3 PL3316867 T3 PL 3316867T3
Authority
PL
Poland
Prior art keywords
methods
tablets
immediate release
containing medicines
making
Prior art date
Application number
PL16736730T
Other languages
English (en)
Inventor
Sanjeev Kothari
Priscilla MANTIK
Alexander MAUERER
Hamid REZAEI
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL3316867T3 publication Critical patent/PL3316867T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16736730T 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek PL3316867T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186556P 2015-06-30 2015-06-30
EP16736730.9A EP3316867B1 (en) 2015-06-30 2016-06-29 Immediate-release tablets containing a drug and processes for forming the tablets
PCT/US2016/039960 WO2017004122A1 (en) 2015-06-30 2016-06-29 Immediate-release tablets containing a drug and processes for forming the tablets

Publications (1)

Publication Number Publication Date
PL3316867T3 true PL3316867T3 (pl) 2021-10-11

Family

ID=56373188

Family Applications (3)

Application Number Title Priority Date Filing Date
PL23198295.0T PL4272735T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL16736730T PL3316867T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL21160939.1T PL3881833T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL23198295.0T PL4272735T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21160939.1T PL3881833T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Country Status (17)

Country Link
US (3) US10478400B2 (pl)
EP (3) EP3316867B1 (pl)
JP (3) JP6914202B2 (pl)
KR (2) KR102716253B1 (pl)
CN (2) CN114177157B (pl)
AR (2) AR105184A1 (pl)
AU (2) AU2016287422B2 (pl)
BR (1) BR112017028218A2 (pl)
CA (1) CA2987912C (pl)
ES (3) ES2969014T3 (pl)
HR (2) HRP20240045T1 (pl)
IL (2) IL256299B2 (pl)
MX (3) MX377955B (pl)
PL (3) PL4272735T3 (pl)
SI (2) SI3316867T1 (pl)
TW (3) TWI795344B (pl)
WO (1) WO2017004122A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3316867T1 (sl) * 2015-06-30 2021-08-31 Genentech, Inc. Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za pripravo tablet
US10751288B2 (en) * 2016-08-23 2020-08-25 New Jersey Institute Of Technology Dry processed surface coated engineering excipients
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3077768A1 (en) * 2017-10-13 2019-04-18 Unichem Laboratories Ltd Pharmaceutical compositions of apremilast
CN110151763A (zh) * 2019-06-26 2019-08-23 深圳市第三人民医院 考比替尼作为制备治疗结核病药物中的应用
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
CA3180509A1 (en) * 2020-06-19 2021-12-23 Sayantan CHATTORAJ Formulation comprising daprodustat
JPWO2023145486A1 (pl) * 2022-01-28 2023-08-03
EP4489730A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
EP1793801A1 (en) * 2005-07-15 2007-06-13 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
US8146000B1 (en) 2005-10-07 2012-03-27 Goodwell Technologies, Inc. Integrated transactional workflows distributed across multiple contact centers
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
MX374707B (es) * 2009-06-22 2025-03-06 Pf Consumer Healthcare 1 Llc Comprimidos de ibuprofeno de sodio y procedimientos de fabricacion de composiciones farmaceuticas que incluyen ibuprofeno de sodio.
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
CA2835760A1 (en) * 2011-06-03 2012-12-06 F. Hoffmann-La Roche Ag Methods of treating mesothelioma with a pi3k inhibitor compound
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
RS67339B1 (sr) * 2011-12-27 2025-11-28 Amgen Europe Gmbh Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
SG10201706196XA (en) * 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
HK1206605A1 (en) * 2012-08-17 2016-01-15 霍夫曼-拉罗奇有限公司 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
EA028301B1 (ru) * 2013-03-06 2017-10-31 Новартис Аг Составы с органическими соединениями
CN117731786A (zh) * 2013-07-12 2024-03-22 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
UA115815C2 (uk) * 2013-07-30 2017-12-26 Гіліад Коннектікут, Інк. Склад на основі інгібіторів syk
SG11201604903VA (en) * 2013-12-16 2016-07-28 Hoffmann La Roche Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
SI3316867T1 (sl) 2015-06-30 2021-08-31 Genentech, Inc. Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za pripravo tablet
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
HK1254389A1 (zh) 2019-07-19
EP3316867B1 (en) 2021-03-10
SI3316867T1 (sl) 2021-08-31
CN114177157A (zh) 2022-03-15
SI3881833T1 (sl) 2024-03-29
MX2017016163A (es) 2018-08-15
WO2017004122A1 (en) 2017-01-05
CN108135854A (zh) 2018-06-08
AR121624A2 (es) 2022-06-22
HRP20240045T1 (hr) 2024-03-29
KR102716253B1 (ko) 2024-10-11
IL256299B1 (en) 2023-07-01
MX2022015606A (es) 2023-02-01
TWI872459B (zh) 2025-02-11
EP3316867A1 (en) 2018-05-09
BR112017028218A2 (pt) 2018-08-28
AU2022201067A1 (en) 2022-03-10
JP7232284B2 (ja) 2023-03-02
IL303352B2 (en) 2025-10-01
HRP20210828T1 (hr) 2021-07-09
IL303352B1 (en) 2025-06-01
TW201705944A (zh) 2017-02-16
TWI804919B (zh) 2023-06-11
TWI795344B (zh) 2023-03-11
TW202206068A (zh) 2022-02-16
CA2987912A1 (en) 2017-01-05
EP4272735B1 (en) 2025-06-18
PL3881833T3 (pl) 2024-05-13
JP6914202B2 (ja) 2021-08-04
KR20240152414A (ko) 2024-10-21
CN114177157B (zh) 2024-08-02
EP4272735A1 (en) 2023-11-08
MX2020013162A (es) 2021-02-18
US10478400B2 (en) 2019-11-19
MX377955B (es) 2025-03-10
EP3881833A1 (en) 2021-09-22
EP3881833B1 (en) 2023-11-01
ES2871175T3 (es) 2021-10-28
AU2016287422B2 (en) 2021-11-18
AR105184A1 (es) 2017-09-13
PL4272735T3 (pl) 2025-10-06
KR20180021814A (ko) 2018-03-05
JP7607062B2 (ja) 2024-12-26
ES3036390T3 (en) 2025-09-18
JP2018519305A (ja) 2018-07-19
EP4272735C0 (en) 2025-06-18
IL256299A (en) 2018-02-28
JP2021138716A (ja) 2021-09-16
IL256299B2 (en) 2023-11-01
TW202337463A (zh) 2023-10-01
IL303352A (en) 2023-08-01
CN108135854B (zh) 2022-03-11
CA2987912C (en) 2023-01-24
ES2969014T3 (es) 2024-05-16
US20220339111A1 (en) 2022-10-27
US20180116966A1 (en) 2018-05-03
KR102881659B1 (ko) 2025-11-06
JP2023071769A (ja) 2023-05-23
US20200085749A1 (en) 2020-03-19
AU2016287422A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
PL3316867T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
HUE058677T2 (hu) Meloxicamot tartalmazó gyógyászati készítmény
EP3513809A4 (en) MEDICAL COMPOSITION
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
EP3164406C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
DK2970291T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af et medikament
HUE055357T2 (hu) Vegyületek kompozíciói és azok alkalmazásai
EP3424940A4 (en) Radiolabeled drug
IL264386A (en) New cannabis tablet formulations and compositions and methods of making the same
HUE048503T2 (hu) Dihidropirimidin-2-on vegyületek és gyógyszerészeti alkalmazásai
DK3357522T3 (da) Coatet medicinsk genstand til lægemiddelsfrigivelse
ZA201902379B (en) Extended release pharmaceutical composition of clozapine
HRP20181507T1 (hr) Modificirana sulfamidaza i njena proizvodnja
EP2987489A4 (en) MEDICINAL FORMULATION WITH DELAYED RELEASE
EP2946777C0 (en) MEDICINE FOR THE TREATMENT OF A NEUROPATHIC DISEASE
HUE050565T2 (hu) Pirazolotiazol vegyület és azt tartalmazó gyógyszer
HUE050697T2 (hu) Gyógyszerkészítmények és ezek alkalmazása
EP3181125C0 (en) CAPSULE FORMULATION
EP3441073A4 (en) MEDICAL COMPOSITION
DK3215130T3 (da) Farmaceutisk sammensætning omfattende bisoprolol og perindoril
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
LT3174398T (lt) Vaflio gamybos būdas ir konditerijos gaminys, apimantis minėtą vaflį
EP3134067C0 (en) VETERINARY COMPOSITION